Bayer secures approval in the EU for Xarelto® (rivaroxaban) for patients with coronary or peripheral artery disease

The European Commission (EC) has approved a regimen of Xarelto® (rivaroxaban) 2.5 mg twice daily plus acetylsalicylic acid (ASA) 75-100 mg once daily for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk for ischemic events.